ConductScience.org, home

Paper28367239

Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.

Zheng Z and 9 others. J Cancer, 2017. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations. Papers, record 28367239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28367239

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
PubMed
Journal
J Cancer
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.31
iCite
Revised in PubMed
2022-03-11
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zheng ZZhen
2Jin XXiance
3Lin BBaochai
4Su HHuafang
5Chen HHanbin
6Fei SShaoran
7Zhao LLihao
8Deng XXia
9Xie DDeyao
10Xie CCongying

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119692684Screening for epidermal growth factor receptor mutations in lung cancer.N Engl J Med2009https://conductscience.org/library/papers/19692684PubMed
217085664Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.Clin Cancer Res2006https://conductscience.org/library/papers/17085664PubMed
318779611Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.J Clin Oncol2008https://conductscience.org/library/papers/18779611PubMed
415197804
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Cancer2004https://conductscience.org/library/papers/15197804PubMed
522700443Cancer treatment and survivorship statistics, 2012.CA Cancer J Clin2012https://conductscience.org/library/papers/22700443PubMed
620195171Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.J Thorac Oncol2010https://conductscience.org/library/papers/20195171PubMed
712829672Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.J Clin Oncol2003https://conductscience.org/library/papers/12829672PubMed
825855621Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.Jpn J Clin Oncol2015https://conductscience.org/library/papers/25855621PubMed
920573926Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med2010https://conductscience.org/library/papers/20573926PubMed
1025034225Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.Oncology2014https://conductscience.org/library/papers/25034225PubMed
1123341526Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.J Clin Oncol2013https://conductscience.org/library/papers/23341526PubMed
1219680293Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.Oncogene2009https://conductscience.org/library/papers/19680293PubMed
1323871711Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.Lung Cancer2013https://conductscience.org/library/papers/23871711PubMed
1417008692Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.J Clin Oncol2006https://conductscience.org/library/papers/17008692PubMed
1523816558The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer.Chin J Cancer2014https://conductscience.org/library/papers/23816558PubMed
1619939491Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.Lung Cancer2010https://conductscience.org/library/papers/19939491PubMed
1725419145EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data.Onco Targets Ther2014https://conductscience.org/library/papers/25419145PubMed
1820677647[Estimation and projection of lung cancer incidence and mortality in China].Zhongguo Fei Ai Za Zhi2010https://conductscience.org/library/papers/20677647PubMed
1921531810Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.Clin Cancer Res2011https://conductscience.org/library/papers/21531810PubMed
2022677429Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.Lung Cancer2012https://conductscience.org/library/papers/22677429PubMed

See all 46 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
41377006Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning.J Thorac Dis2025https://conductscience.org/library/papers/41377006PubMed
40458063Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.Future Oncol2025https://conductscience.org/library/papers/40458063PubMed
37321664Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer.BMJ Open Respir Res2023https://conductscience.org/library/papers/37321664PubMed
29552210Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma.Oncol Lett2018https://conductscience.org/library/papers/29552210PubMed
29447182The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis.PLoS One2018https://conductscience.org/library/papers/29447182PubMed
29353978Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis.Chin J Cancer Res2017https://conductscience.org/library/papers/29353978PubMed
28651600Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA).Radiat Oncol2017https://conductscience.org/library/papers/28651600PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGF1950PubTator's text mininghttps://conductscience.org/library/genes/1950NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28367239

GET https://conductscience.org/api/papers/v1/28367239/references?page=2